

1 **A FEASIBILITY STUDY OF PERIOPERATIVE VITAMIN D SUPPLEMENTATION**
2 **IN PATIENTS UNDERGOING COLORECTAL CANCER RESECTION**

3
4 **Authors:** P.G. Vaughan-Shaw^{1,2}, L.F. Buijs^{1,2}, J.P. Blackmur^{1,2}, A. Ewing^{1,2}, E.
5 Theodoratou^{2,3}, Li-Yin. Ooi^{1,2,4}, F.V.N. Din², S.M. Farrington², M.G. Dunlop^{1,2}

6
7 **Affiliations:**

8 ¹MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh,
9 Edinburgh, United Kingdom; ²Cancer Research UK Edinburgh Centre, Institute of Genetics
10 and Cancer, University of Edinburgh, Edinburgh, United Kingdom. ³Centre for Global Health
11 Research, Usher Institute for Population Health Sciences and Informatics, University of
12 Edinburgh, Edinburgh, United Kingdom. ⁴Department of Pathology, National University
13 Hospital, Singapore.

14
15 **Corresponding Author:**

16 Professor MG Dunlop. Institute of Genetics and Cancer, University of Edinburgh and MRC
17 Human Genetics Unit, Western General Hospital Edinburgh, Crewe Road, Edinburgh, EH4
18 2XU, United Kingdom. ORCID [0000-0002-3033-5851](https://orcid.org/0000-0002-3033-5851); T: +44 (0)131 651 8500 E:
19 malcolm.dunlop@ed.ac.uk

20
21 **Running title:** Perioperative vitamin D supplementation in patients with colorectal cancer

22
23 **Abbreviations**

24	25OHD	25-hydroxyvitamin D
25	AJCC	American Joint Committee on Cancer stage
26	BMI	Body mass index
27	CI	Confidence interval
28	CRC	Colorectal cancer
29	CRP	C-reactive protein
30	SIR	Systemic inflammatory response
31	SCOVIDS	Scottish Vitamin D study
32	SOCCS	Study of Colorectal Cancer in Scotland

1 **ABSTRACT**

2

3 **BACKGROUND**

4 Post-operative vitamin D supplementation improves CRC survival outcomes in randomised
5 trials. The aim of this study was to test the feasibility, safety and efficacy of vitamin D in the
6 pre- and perioperative period in patients undergoing CRC surgery.

7

8 **METHODS**

9 Patients were given 3200IU oral cholecalciferol per day perioperatively. Serial serum
10 25OHD was measured by liquid chromatography tandem mass spectrometry and compared to
11 untreated CRC controls. 25OHD/CRP levels were compared using adjusted generalized
12 linear mixed-effects models.

13

14 **RESULTS**

15 122 patients underwent serial perioperative sampling, including 41 patients given high-dose
16 perioperative supplementation. 25OHD was higher in patients given high-dose
17 supplementation compared to controls at all peri-operative timepoints ($P < 0.001$) and
18 supplementation attenuated the post-operative drop in 25OHD (46% vs 24% drop). Rate of
19 vitamin D insufficiency was significantly less in those on supplementation (14% vs. 56%,
20 $P = 0.003$), with multivariate modelling indicating a ~ 60 nmol/l higher 25OHD compared to
21 control patients ($P = 1.22E-15$). Supplementation was associated with lower peri-operative
22 CRP ($P = 0.035$).

23

24 **DISCUSSIONS**

25 High dose pre-operative vitamin D supplementation is associated with higher perioperative
26 25OHD levels, lower rates of vitamin D insufficiency and reduced early postoperative CRP.
27 These findings provide compelling rationale for early initiation of vitamin D supplementation
28 after a diagnosis of CRC.

29

30

31

32

33

1 **ADDITIONAL INFORMATION**

2 **Acknowledgements:** We acknowledge the excellent technical support from Marion
3 Walker and Stuart Reid. We are grateful to Donna Markie, and all those who continue to
4 contribute to recruitment, data collection, and data curation for the Study of Colorectal
5 Cancer in Scotland studies. We acknowledge the nursing and study facilities provided by
6 the Edinburgh Wellcome Trust Clinical Research Facility. Finally, we acknowledge that
7 these studies would not be possible without the patients and surgeons who take part.

8 The manuscript is available on medRxiv, MEDRXIV/2022/278022

9
10

Authors' contributions

11 Study concepts: PVS, LFB, JPB, LYO, FVND, SMF, MGD

12 Study design: PVS, LFB, LYO, JPB, ET, SMF, MGD

13 Data acquisition: PVS, LYO, LFB, JPB,

14 Quality control of data and algorithms: PVS, AE

15 Data analysis and interpretation: PVS, AE

16 Statistical analysis: PVS, AE

17 Manuscript preparation: PVS, LFB, JPB, AE, MT, SMF, MGD

18 Manuscript editing: PVS, LFB, JPB, AE, MT, SMF, MGD

19 Manuscript review: PVS, ET, AE, FVND, SMF, MGD

20 Funding acquisition: PVS, SMF, MGD

21 Project administration: MGD

22 Supervision: MGD, SMF

23

24 **Ethics approval and consent to participate:** Participants provided informed written
25 consent, and research was approved by local research ethics committees (SOCCS
26 11/SS/0109 and 01/0/05; SCOVIDS 13/SS/0248) and National Health Service
27 management (SOCCS 2013/0014, 2003/W/GEN/05; SCOVIDS 2014/0058).

28

29 **Consent for publication:** Not applicable

30

31 **Data Availability Statement:** Data available upon reasonable request

32 **Competing interests:** The authors declare no potential conflicts of interest.

1 **Funding information:** This work was supported by funding for the infrastructure and
2 staffing of the Edinburgh CRUK Cancer Research Centre; CRUK programme grant
3 C348/A18927 (MGD). The study received a grant from Bowel Disease Research
4 Foundation (now Bowel Research UK). PVS was supported by a MRC Clinical Research
5 Training Fellowship (MR/M004007/1). LYO is supported by a Cancer Research UK
6 Research Training Fellowship (C10195/A12996). This work was also funded by a grant
7 to MGD as Project Leader with the MRC Human Genetics Unit Centre Grant
8 (U127527202 and U127527198 from 1/4/18). JB is supported by an Edinburgh Clinical
9 Academic Track (ECAT) linked Cancer Research UK Clinical Research Fellowship
10 (C157/A23218).

11 **Role of the Funding Source:** The funders had no role in design, undertaking, analysis or
12 writing of the above study.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1

2

3

INTRODUCTION

4

5

6 Despite substantial improvement in mortality from colorectal cancer (CRC) over
7 recent years, ~16,600 people die from CRC each year in the UK ¹. Whilst surgery remains the
8 mainstay of therapy, new therapeutic approaches are required. Compelling evidence from
9 observational studies ² demonstrate a link between low vitamin D and poor outcomes
10 following a diagnosis of colorectal cancer ³⁻⁸, while a recent meta-analysis of trial data
11 demonstrating a 30% reduction in adverse CRC outcomes with supplementation ⁹. Plasma
12 25-hydroxyvitamin D (25OHD) levels in CRC patients are consistently lower than in
13 population controls ¹⁰, yet a key unanswered question is whether supplementation could
14 provide benefit from the time of diagnosis. Abdominal surgery is a major physiological insult
15 and 25OHD (the best marker and storage form of vitamin D) falls dramatically following
16 bowel cancer surgery ². 25OHD is also known to decrease following orthopaedic, cardiac and
17 gynaecological surgery ¹¹⁻¹⁶. Several explanations are proposed to explain the observed
18 decrease, including circulatory fluid changes i.e. haemodilution ^{14,17} and/or systemic
19 inflammatory responses to surgery. It follows that because 25OHD depletion is associated
20 with adverse survival outcomes and supplementation can improve survival, studies to define
21 when to initiate supplementation are required. While no study to date has assessed the impact
22 of vitamin D supplements in patients undergoing colorectal cancer resection, cholecalciferol
23 (vitamin D3) supplements have been shown to significantly improve 25OHD levels in
24 patients with a historical diagnosis of CRC ¹⁸ and in patients undergoing chemotherapy for
25 CRC ¹⁹.

25

26

27

28

29

Here, we have investigated the perioperative temporal variation in plasma 25OHD
and CRP by serially sampling patients undergoing CRC resectional surgery and aimed to
demonstrate that vitamin D supplementation is feasible, safe and effective in the
perioperative period. These data will be essential in informing the design of future
randomised trials of vitamin D and survival outcomes after colorectal cancer surgery.

30

31

METHODS

32

33

34

35

The Study of Colorectal Cancer in Scotland (SOCCS) study is a national population-
based case-control study designed to identify genetic and environmental factors that have an
impact on CRC risk and survival outcome ²⁰. The Scottish Vitamin D study (SCOVIDS) is a

1 single-centre study designed to investigate the link between vitamin D, CRC risk and
2 survival. Participants provided informed written consent, and research was approved by local
3 research ethics committees (SOCCS 11/SS/0109 and 01/0/05; SCOVIDS 13/SS/0248) and
4 National Health Service management (SOCCS 2013/0014, 2003/W/GEN/05; SCOVIDS
5 2014/0058) and registered with clinicaltrials.gov (NCT05506696). Clinical and sampling
6 variables were collected from patient case notes and pathology records, entered into a
7 prospective study database and extracted for analysis. We used data from patients recruited
8 between 2012 and 2013 who underwent serial sampling during the preoperative and
9 immediate postoperative period, as previously described ². We then recruited patients to
10 undergo high dose pre- and perioperative oral vitamin D supplementation (3200IU/ day
11 cholecalciferol, Fultium-D3, Internis Pharmaceuticals Ltd, Huddersfield, UK), alongside a
12 contemporaneous control group. All patients eligible for supplementation but not already
13 established on vitamin D or multivitamin supplementation were considered for inclusion
14 (Supplementary Table 1). Whether the patient was recruited by our research nurse, or surgical
15 research fellows (PVS/ LB) determined whether they were allocated to the control or
16 supplementation group respectively, itself determined by timetabling and clinic availability of
17 each recruiter. Patients administered supplementation took 3200IU everyday preoperatively,
18 including on the morning of surgery, and in the early postoperative period except where
19 postoperative ileus occurred. Given the pragmatic methodology, no alteration to the normal
20 patient pathway occurred and there was marked variation in duration of preoperative
21 supplementation between patients, in part due to delays and disruption from the COVID-19
22 pandemic. Recruitment was paused during the first wave of the COVID-19 pandemic,
23 significantly impacting on total study recruitment, while restrictions on hospital appointments
24 and non-clinical sampling limited the number of post-discharge samples that could be taken.

25

26 **Plasma vitamin D assay**

27 Samples were taken at preoperative assessment clinic and/or the day of surgery, and
28 postoperatively (on the ward at 1-2 days, 3-5 days, 6-9 days) and at the first postoperative
29 clinic appointment. COVID-19 restrictions and the emergency of telephone follow-up
30 significantly impacted the ability to perform post-discharge sampling.

31 Plasma was extracted from blood sampled by venepuncture from a peripheral arm vein. To
32 minimise any potential analytical variation in plasma 25OHD measurement, all samples were
33 assayed in a single United Kingdom Accreditation Service (UKAS) accredited laboratory
34 using a method traceable to National Standards of Science and Technology standard

1 reference material. 21 Total 25OHD (25OHD2 and 25OHD3) was measured by liquid
2 chromatography tandem mass spectrometry and analysed using the Waters® Xevo® TQ-S
3 system (Waters Limited, Wilmslow, UK).

4

5 **Plasma CRP assay**

6 To assess for potential relevance of the systemic inflammatory response, samples
7 were assayed for CRP in a NHS Biochemistry Laboratory serving our hospital. CRP was
8 measured using the Abbott Architect C series clinical chemistry analyser to standard
9 sensitivity protocol, with the range of output values 0.2-480 mg/l. CRP internal quality
10 control was performed daily, with 3 control samples assayed twice per day. Target mean of
11 the three control samples was 3.2, 8.3 and 27.5mg/l with actual observed mean over 6 months
12 of 3.2, 8.4 and 27.8mg/l respectively from 5151 completed assays. Coefficients of variation
13 were 3.42%, 2.34% and 2.05% respectively.

14

15 **Sample size considerations**

16 Data from our previously published control group ² was used to inform a power
17 calculation, with the current study design powered to identify a 50% suppression of the day
18 1-2 postoperative drop in 25OHD with supplementation ($\alpha=0.05$ [one-tailed]; $\beta=0.10$,
19 calculated sample size in each arm = 54).

20

21 **Patient and public involvement**

22 This project is relevant to biomarker prediction and risk stratification and was
23 assigned high priority in the seminal Association of Coloproctology of Great Britain and
24 Ireland (ACPGBI) Delphi process ²². After draft protocol design, we developed our lay
25 summary and PPI questionnaire in collaboration with the University of Edinburgh Patient
26 Advisory Group and Patient Liaison Group of the ACPGBI. Thereafter we surveyed eight
27 patients with colorectal cancer to assess the acceptability of the proposed serial sampling
28 study and help inform our final study design.

29

30 **Patient, Tumour and Treatment-Related Variables**

31 We considered and adjusted for patient-related factors previously established to
32 influence 25OHD levels (age, sex, body mass index (BMI). ²³⁻²⁵ Tumour and treatment-
33 related variables were collected to investigate putative effect on 25OHD, including American

1 Joint Committee on Cancer (AJCC) stage. Information on tumour site, multiplicity and
2 clinico-pathologic staging were obtained from clinical records, along with preoperative
3 imaging. By using collated pathology, imaging, and clinical data; tumour stage was mapped
4 onto the AJCC staging system (AJCC stage I to IV).

5 6 **Statistical analysis**

7 All statistical analysis was undertaken in R (version 4.1.0) [26]. To account for
8 seasonal differences in vitamin D status, reported 25OHD level was May-standardized by
9 adjusting for sampling month using differences in age- and sex-adjusted monthly averages
10 generated from SOCCS control data [27]. A linear mixed-effects model was applied to the
11 serially sampled data to examine the association between perioperative changes in CRP and
12 25OHD (log-transformed) and treatment group. This multivariable model adjusted for age,
13 gender, BMI and AJCC tumour stage. The package ‘*emmeans*’ was used to compute contrasts
14 between estimated marginal means to evaluate potential differences in 25OHD between
15 treatment groups at each timepoint. Finally, a binomial generalized linear mixed-effects
16 model was applied to test for differences in rate of vitamin D insufficiency between treatment
17 groups and at each peri-operative timepoint, adjusting for age, gender, BMI and AJCC
18 tumour stage.

19 20 **RESULTS**

21 **Baseline demographics**

22 We recruited a total of 122 patients who underwent serial perioperative sampling at
23 up to 6 time-points, including 41 patients who received high-dose perioperative vitamin D
24 supplementation (Table 1). No significant differences in baseline clinicopathological
25 variables between the groups were observed. No differences between the previously
26 published control group and newly recruited control group were observed, including in
27 baseline 25OHD (46.3 vs. 47.6nmol/l, P=0.86; Supplementary Table 2).

28 29 **Efficacy and safety of perioperative supplementation**

30 No serious adverse events occurred in those taking perioperative supplementation,
31 which was well tolerated in study participants. In patients with both a pre- and post-
32 supplementation sample (N=13), supplementation induced a 2.1 fold-increase (48.2nmol/
33 95%CI 20.7-75.6; P=0.01) in 25OHD level (Table 2, Figure 1). Overall, patients took
34 preoperative supplementation for median 25 days (range 9-84) with no correlation between

1 number of days' supplementation and either increase in 25OHD ($R=-0.20$, $P=0.5$) or 25OHD
2 level on day of surgery ($R=0.14$, $P=0.39$). Dose diaries assessed for 8 subjects, indicated high
3 compliance with daily supplementation (316 out of 319 days perioperative supplementation
4 completed).

5 Supplemented patients had higher 25OHD levels on the day of surgery ($P=8.2E-12$,
6 Table 2) and in the early postoperative period when compared to control patients (e.g. 1-2
7 days 80.9nmol/l vs. 26.7nmol/l, $P=3.6E-15$; Table 2, Figure 1). Crucially, the multivariate
8 fixed-effects model confirmed a significant and clinically relevant impact of supplementation
9 on perioperative 25OHD levels, after adjusting for age, gender, BMI and AJCC stage (Table
10 2; Supplementary Table 3). Supplementation also reduced the prevalence of perioperative
11 vitamin D insufficiency (25OHD<50nmol/l), with 14% of supplemented patients having
12 early postoperative insufficiency compared to 56% of control patients ($P=0.003$, Table 4).
13 Finally, although 25OHD levels dropped in all treatment groups following surgery,
14 supplementation attenuated the early post-operative drop (e.g. 46% drop vs. 24% drop at days
15 1-2, $P=0.0003$). (Figure 1; Supplementary Table 4).

16

17 **Impact of supplementation on postoperative CRP levels**

18 CRP levels assayed at the same time as 25OHD were compared across treatment
19 groups. As expected, CRP increased postoperatively in all groups, yet the increase appeared
20 less in those taking high-dose supplementation, with lower early postoperative CRP levels
21 seen in these patients (e.g. 3-5 days 80.5mg/l vs. 129mg/l, $P=0.04$, Table 5, Supplementary
22 Figure 2). The multivariate mixed-effects model indicated that supplementation had a
23 modest impact on peri-operative CRP levels after adjusting for age, gender, BMI and AJCC
24 stage ($P=0.035$; Table 3; Supplementary Table 5).

25

26 **DISCUSSION**

27 High-dose perioperative vitamin D supplementation is safe and well tolerated in
28 patients undergoing colorectal cancer surgery. Compared to control patients, supplementation
29 induces a significant increase in perioperative 25OHD levels, a smaller relative drop in
30 25OHD following surgery and lower rates of postoperative vitamin D insufficiency.
31 Meanwhile, early postoperative CRP appears to lower in patients on supplementation
32 supporting the role of vitamin D in regulation of inflammatory processes.

1 This study provides evidence for a beneficial effect of vitamin D supplementation on
2 perioperative vitamin D status while a recent meta-analysis of RCT data reported a
3 significant reduction in CRC mortality with vitamin D supplementation ^{9,26}. Taken together,
4 these data support early initiation of supplementation at the point of CRC diagnosis. While
5 vitamin D repletion has already been shown to be feasible in patients undergoing
6 chemotherapy ^{3,4,19}, no study to date has explored its use in CRC patients in the perioperative
7 period. Vitamin D levels are known to drop following surgery ², which is confirmed here in
8 all treatment groups. Here, we demonstrate that despite the insult of resectional cancer
9 surgery, and associated changes in gut motility and absorption, perioperative supplementation
10 induces a marked increase in preoperative 25OHD levels and attenuates the drop in 25OHD
11 following surgery. Given the tight physiological autoregulation that exists, it is unlikely that
12 mechanisms that confer the observed beneficial impact of vitamin D on CRC survival occur
13 in a linear manner, but rather that a threshold effect exists. Given that our previous work
14 suggests that a 25OHD threshold of ~45-50nmol/l appears to most strongly associate with
15 survival, it is relevant that in the current study supplementation significantly reduced
16 postoperative vitamin D insufficiency (25OHD<50nmol/l).

17 To date, no trial has investigated the optimum time to initiate supplementation.
18 Indeed, few of the supplementation trials in CRC patients include patients undergoing
19 curative resection, with one such trial (AMATERASU trial), recruiting patients at the first
20 outpatient visit after surgery ⁵. It is relevant that in population trials where recruitment and
21 supplementation occur before the diagnosis of incident cases of CRC, a beneficial effect of
22 vitamin D supplementation on survival is still seen. Furthermore, 25OHD levels sampled
23 preoperatively and at the earliest postoperative timepoint (<6 months) are already associated
24 with survival in observational data ². Therefore, given that this cheap supplement has now
25 been shown to be safe and well tolerated in the perioperative period, there is compelling
26 rationale to start at the point of diagnosis, especially given the increasing use of neo-adjuvant
27 therapy which can delay resectional CRC surgery for many months.

28 Previous pre-clinical and human intervention studies provide clues to the mechanisms
29 that may underlie the beneficial effect of supplementation on CRC survival and provide no
30 contra-indication to earlier supplementation. 1,25-dihydroxyvitamin D₃ modulates immune
31 and inflammatory pathway genes in large bowel epithelium ²⁷ while oral supplementation
32 induces transcriptomic changes in rectal mucosa that are linked to anti-tumour effects ²⁸.
33 Vitamin D also regulates multiple inflammatory processes both *in vitro* and *in vivo*, including
34 those involved in CRC such as oxidative stress and the cyclooxygenase and NF-κB pathways

1 ^{29,30}. Effects on inflammatory processes are consistent with the lower postoperative CRP
2 levels in supplemented patients in the current study, supporting the notion that vitamin D
3 might be causally implicated in the SIR response following surgery. This provides further
4 potential mechanism to improved survival outcomes with supplementation given that CRP,
5 an established marker of inflammation, is strongly correlated with CRC survival ^{31,32}.

6 The current study has a number of limitations. We acknowledge that supplemented
7 patients recruited in 2020 were compared against a combined control group including
8 patients recruited in 2013. As such, unmeasured historical differences in demographics,
9 genetic background (e.g. vitamin D receptor or pathway SNPs ³³) or clinical factors may
10 confound the observed effect of supplementation. However, we observed no difference in
11 baseline or peri-operative 25OHD between the two control groups. Furthermore, mixed-
12 modelling identified a significant association between supplementation and increased 25OHD
13 level when comparing supplemented patients with the newest control cohort (~60nmol/l;
14 P=3.51E-08). Nevertheless, we cannot fully exclude the possibility that differences in
15 perioperative 25OHD levels are due to factors other than supplementation (i.e. confounding
16 factors) because this was not a randomised study. Third, the power of our study was limited
17 by COVID-19 which markedly impacted total study recruitment and sampling. Finally, while
18 our data supports the early initiation of supplementation in patients undergoing CRC surgery
19 given its effects on 25OHD level and extrapolating from previous trial evidence of survival
20 benefit, we do not provide direct evidence of survival benefit from early supplementation.

21 In conclusion, we report for the first time on the feasibility and safety of perioperative
22 vitamin D supplementation in patients undergoing colorectal cancer surgery. We identified a
23 positive effect of supplementation on perioperative 25OHD levels with lower rates of
24 postoperative vitamin D insufficiency and reduced early postoperative CRP. Our findings
25 provide compelling rationale for early initiation of vitamin D supplementation after a
26 diagnosis of CRC. Future randomised trials of supplementation with a defined endpoint of a
27 beneficial effect on survival outcomes should consider supplementation from the point of
28 diagnosis.

29

30

31 **References**


32

- 33 1. CRUK. Cancer statistics. [https://www.cancerresearchuk.org/health-](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type)
34 [professional/cancer-statistics/statistics-by-cancer-type](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type). Accessed 24/12/2019, 2019
35 (2019).

- 1 2. Vaughan-Shaw PG, Zgaga L, Ooi LY, Theodoratou E, Timofeeva M, Svinti V *et al.*
2 Low plasma vitamin D is associated with adverse colorectal cancer survival after
3 surgical resection, independent of systemic inflammatory response. *Gut* 2020; **69**(1):
4 103-111; e-pub ahead of print 2019/04/27; doi 10.1136/gutjnl-2018-317922.
- 5 3. Antunac Golubic Z, Barsic I, Librenjak N, Plestina S. Vitamin D Supplementation
6 and Survival in Metastatic Colorectal Cancer. *Nutr Cancer* 2018; **70**(3): 413-417; e-
7 pub ahead of print 2018/03/14; doi 10.1080/01635581.2018.1445766.
- 8 4. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM *et al.* Effect
9 of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free
10 Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The
11 SUNSHINE Randomized Clinical Trial. *JAMA* 2019; **321**(14): 1370-1379; e-pub
12 ahead of print 2019/04/10; doi 10.1001/jama.2019.2402.
- 13 5. Urashima M, Ohdaira H, Akutsu T, Okada S, Yoshida M, Kitajima M *et al.* Effect of
14 Vitamin D Supplementation on Relapse-Free Survival Among Patients With
15 Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. *JAMA*
16 2019; **321**(14): 1361-1369; e-pub ahead of print 2019/04/10; doi
17 10.1001/jama.2019.2210.
- 18 6. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3
19 (cholecalciferol) supplementation on fractures and mortality in men and women living
20 in the community: randomised double blind controlled trial. *BMJ* 2003; **326**(7387):
21 469; e-pub ahead of print 2003/03/01; doi 10.1136/bmj.326.7387.469
22 326/7387/469 [pii].
- 23 7. Manson JE, Bassuk SS, Buring JE, Group VR. Principal results of the VITamin D and
24 Omega-3 Trial (VITAL) and updated meta-analyses of relevant vitamin D trials. *J*
25 *Steroid Biochem Mol Biol* 2019; **198**: 105522; e-pub ahead of print 2019/11/17; doi
26 10.1016/j.jsbmb.2019.105522.
- 27 8. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan
28 MJ *et al.* Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N*
29 *Engl J Med* 2006; **354**(7): 684-696; e-pub ahead of print 2006/02/17; doi 354/7/684
30 [pii]
31 10.1056/NEJMoa055222.
- 32 9. Vaughan-Shaw PG, Buijs LF, Blackmur JP, Theodoratou E, Zgaga L, Din FVN *et al.*
33 The effect of vitamin D supplementation on survival in patients with colorectal
34 cancer: systematic review and meta-analysis of randomised controlled trials. *Br J*
35 *Cancer* 2020; e-pub ahead of print 2020/09/16; doi 10.1038/s41416-020-01060-8.
- 36 10. Theodoratou E, Palmer T, Zgaga L, Farrington SM, McKeigue P, Din FV *et al.*
37 Instrumental variable estimation of the causal effect of plasma 25-hydroxy-vitamin D
38 on colorectal cancer risk: a mendelian randomization analysis. *PLoS One* 2012; **7**(6):
39 e37662; e-pub ahead of print 2012/06/16; doi 10.1371/journal.pone.0037662
40 PONE-D-11-23990 [pii].
- 41 11. Skuladottir GV, Cohen A, Arnar DO, Hougaard DM, Torfason B, Palsson R *et al.*
42 Plasma 25-hydroxyvitamin D2 and D3 levels and incidence of postoperative atrial
43 fibrillation. *J Nutr Sci* 2016; **5**: e10; doi 10.1017/jns.2015.38.
- 44 12. Pilka R, Marek R, Adam T, Kudela M, Ondrova D, Neubert D *et al.* Systemic
45 Inflammatory Response After Open, Laparoscopic and Robotic Surgery in
46 Endometrial Cancer Patients. *Anticancer Res* 2016; **36**(6): 2909-2922.
- 47 13. Louw JA, Werbeck A, Louw ME, Kotze TJ, Cooper R, Labadarios D. Blood vitamin
48 concentrations during the acute-phase response. *Crit Care Med* 1992; **20**(7): 934-941.
- 49 14. McNally JD, Menon K, Chakraborty P, Fisher L, Williams KA, Al-Dirbashi OY *et al.*
50 Impact of anesthesia and surgery for congenital heart disease on the vitamin d status

- 1 of infants and children: a prospective longitudinal study. *Anesthesiology* 2013;
2 **119**(1): 71-80; doi 10.1097/ALN.0b013e31828ce817.
- 3 15. Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DS *et al.* The relation
4 between acute changes in the systemic inflammatory response and plasma 25-
5 hydroxyvitamin D concentrations after elective knee arthroplasty. *Am J Clin Nutr*
6 2011; **93**(5): 1006-1011; doi 10.3945/ajcn.110.008490.
- 7 16. Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL *et al.*
8 Vitamin D: a negative acute phase reactant. *J Clin Pathol* 2013; **66**(7): 620-622; doi
9 10.1136/jclinpath-2012-201301.
- 10 17. Krishnan A, Ochola J, Mundy J, Jones M, Kruger P, Duncan E *et al.* Acute fluid
11 shifts influence the assessment of serum vitamin D status in critically ill patients. *Crit*
12 *Care* 2010; **14**(6): R216; doi 10.1186/cc9341.
- 13 18. Vaughan-Shaw P.G. OLY, Timofeeva M., Svinti V., Walker M., Farrington S.M., Din
14 F.V., Dunlop M.G. Peri-operative plasma vitamin D level in colorectal cancer patients
15 and effect of vitamin D supplementation on colorectal cancer patients. *Colorectal*
16 *disease : the official journal of the Association of Coloproctology of Great Britain*
17 *and Ireland* 2016; **18**(Supp 2): 34.
- 18 19. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D *et al.*
19 Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment
20 Initiation. *J Gastrointest Cancer* 2019; **50**(4): 769-779; e-pub ahead of print
21 2018/07/31; doi 10.1007/s12029-018-0147-7.
- 22 20. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R *et al.*
23 Dietary flavonoids and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers*
24 *Prev* 2007; **16**(4): 684-693; e-pub ahead of print 2007/04/10; doi 16/4/684 [pii]
25 10.1158/1055-9965.EPI-06-0785.
- 26 21. Knox S, Harris J, Calton L, Wallace AM. A simple automated solid-phase extraction
27 procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid
28 chromatography-tandem mass spectrometry. *Ann Clin Biochem* 2009; **46**(Pt 3): 226-
29 230; doi 10.1258/acb.2009.008206.
- 30 22. Tiernan J, Cook A, Geh I, George B, Magill L, Northover J *et al.* Use of a modified
31 Delphi approach to develop research priorities for the association of coloproctology of
32 Great Britain and Ireland. *Colorectal Dis* 2014; **16**(12): 965-970; e-pub ahead of print
33 2014/10/07; doi 10.1111/codi.12790.
- 34 23. Kimlin MG, Lucas RM, Harrison SL, van der Mei I, Armstrong BK, Whiteman DC *et*
35 *al.* The contributions of solar ultraviolet radiation exposure and other determinants to
36 serum 25-hydroxyvitamin D concentrations in Australian adults: the AusD Study. *Am*
37 *J Epidemiol* 2014; **179**(7): 864-874; e-pub ahead of print 2014/02/28; doi kwt446 [pii]
38 10.1093/aje/kwt446.
- 39 24. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA *et al.*
40 Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int* 2009;
41 **20**(11): 1807-1820; doi 10.1007/s00198-009-0954-6.
- 42 25. Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D *et al.* Plasma
43 vitamin D concentration influences survival outcome after a diagnosis of colorectal
44 cancer. *J Clin Oncol* 2014; **32**(23): 2430-2439; doi 10.1200/JCO.2013.54.5947.
- 45 26. Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D
46 supplementation and total cancer incidence and mortality: a meta-analysis of
47 randomized controlled trials. *Ann Oncol* 2019; **30**(5): 733-743; e-pub ahead of print
48 2019/02/24; doi 10.1093/annonc/mdz059.
- 49 27. Protiva P, Pendyala S, Nelson C, Augenlicht LH, Lipkin M, Holt PR. Calcium and
50 1,25-dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in

- 1 the human colon: a human crossover trial. *Am J Clin Nutr* 2016; **103**(5): 1224-1231;
2 doi 10.3945/ajcn.114.105304.
- 3 28. Vaughan-Shaw PG, Grimes G, Blackmur JP, Timofeeva M, Walker M, Ooi LY *et al*.
4 Oral vitamin D supplementation induces transcriptomic changes in rectal mucosa that
5 are linked to anti-tumour effects. *BMC Med* 2021; **19**(1): 174; e-pub ahead of print
6 2021/08/04; doi 10.1186/s12916-021-02044-y.
- 7 29. van Harten-Gerritsen AS, Balvers MG, Witkamp RF, Kampman E, van Duijnhoven
8 FJ. Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of
9 Mechanistic Studies and Future Directions for Epidemiological Studies. *Cancer*
10 *Epidemiol Biomarkers Prev* 2015; **24**(12): 1820-1828; doi 10.1158/1055-9965.EPI-
11 15-0601.
- 12 30. Bostick RM. Effects of supplemental vitamin D and calcium on normal colon tissue
13 and circulating biomarkers of risk for colorectal neoplasms. *The Journal of steroid*
14 *biochemistry and molecular biology* 2015; **148**: 86-95; doi
15 10.1016/j.jsbmb.2015.01.010.
- 16 31. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts
17 survival following curative resection of colorectal cancer. *Br J Surg* 2003; **90**(2): 215-
18 219; doi 10.1002/bjs.4038.
- 19 32. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade
20 of experience in patients with cancer. *Cancer Treat Rev* 2013; **39**(5): 534-540; doi
21 10.1016/j.ctrv.2012.08.003.
- 22 33. Revez JA, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z *et al*. Genome-wide association
23 study identifies 143 loci associated with 25 hydroxyvitamin D concentration. *Nat*
24 *Commun* 2020; **11**(1): 1647; e-pub ahead of print 2020/04/04; doi 10.1038/s41467-
25 020-15421-7.
26



Mean 25OHD

Treatment

- Control
- VitD

Clinic

Pre-op

1-2

3-5

6-9

30-120

Samplepoint, days post-operative

TABLE 1 Clinicopathological demographics of included patients

	Control	VitD	P†
N	81	41	-
Sampling Years	2013-2020	2020	-
Age (years, SD)	66.4 (13.0)	64.7 (14.1)	0.72
Gender (F)	37 (46%)	17 (41%)	0.70
BMI (kg/m², SD)	27.0 (4.4)	28.5 (5.7)	0.11
Baseline 25OHD (median, IQR)	42.5 (31.9)	50.49 (27.79)	0.35
Cancer site			-
Colon	49 (60%)	17 (41%)	0.06
Rectum	32 (40%)	24 (59%)	0.06
Cancer stage			
AJCC 1	26 (32%)	8* (21%)	
AJCC 2	27 (33%)	12 (32%)	
AJCC 3	19 (23%)	17 (45%)	
AJCC 4	9 (11%)	1 (3%)	<i>P</i> trend=0.74

*3 additional patients who underwent neo-adjuvant therapy classified as ypT0 on histological analysis.

TABLE 2 May-adjusted perioperative 25OHD

	Control		High-dose VitD		P†	P*
	N	25OHD	N	25OHD		
Clinic	-	-	13	50.5 (27.8)	NA	NA
Pre-op	81	42.5 (31.9)	40	103.9 (49.5)	8.2E-12	3.34E-15
1-2 days	81	26.7 (20.7)	41	80.9 (39.6)	3.6E-15	3.27E-23
3-5 days	77	28.5 (22.3)	38	92.9 (33.9)	2.9E-13	8.69E-23
6-9 days	60	28 (26.6)	22	82.5 (36.2)	1.1E-06	6.53E-12
30-120 days	61	34.2 (21.5)	15	112 (31.2)	9.4E-08	1.75E-16

*Median 25OHD levels given in nmol/l with IQR. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC*

TABLE 3 Impact of treatment on 25OHD and CRP levels in mixed-effects model

	May-adjusted 25OHD	CRP
Univariate model		
Estimate	60.4nmol/l	2mg/l
P	2.77e-14	0.045
Fully adjusted model		
Estimate	62.2nmol/l	2.59mg/l
P	1.22e-15	0.035

Adjusted model included age, gender, BMI and AJCC

TABLE 4 Perioperative Vitamin D

Timepoint	Control N (%)	High-dose VitD N (%)	P†	P*
Clinic	55 (68%)	3 (8%)	3.06E-09	3.04E-07
Pre-op	69 (86%)	11 (28%)	8.2E-12	1.34E-07
1-2 days	64 (84%)	5 (14%)	3.6E-15	1.39E-08
3-5 days	52 (87%)	4 (20%)	2.9E-13	1.40E-06
6-9 days	55 (68%)	3 (8%)	1.1E-06	3.66E-06
30-120 days	69 (86%)	11 (28%)	9.4E-08	3.04E-07

*Vitamin D insufficiency <50nmol/l. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC.*

TABLE 5 Perioperative CRP levels in control and supplemented patients

Timepoint	Control		VitD		P†	P*
	N	CRP (mg/l, iqr)	N	CRP (mg/l, iqr)		
Pre-op	59	5 (11)	38	3 (9)	0.16	0.04
1-2 days	58	97.5 (62.25)	39	78 (48)	0.049	0.33
3-5 days	57	129 (121)	39	81 (72.6)	0.017	0.04
6-9 days	46	61 (58)	18	54 (75)	0.95	0.90

*Median CRP levels given in mg/l with IQR. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC*